Table 2.
Study details and characteristics of randomised patients at baseline
| Study | Treatment | Total participants | Males | Median age (range) | Median follow-up in months | No. of resected patients (%) | No. of patients with 1–3 liver metastases (%) | Synchronous metastases (%) | Plasma CEA >30 ng/mL at diagnosis (%) | WHO performance status 0 or 1 (%) | Previous adjuvant chemotherapy for primary cancer (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Primrose 2014 | FOLFOX/Surgery/FOLFOX | 128 | 80 | 64 (59–70) | 21 | 93 (93) | 102 (80) | 60 (47) | 31 (24) | 128 (100) | NRf |
| FOLFOX + CET/Surgery/FOLFOX + CET | 129 | 92 | 63 (59–69) | 85 (87) | 97 (75) | 68 (53) | 33 (26) | 126 (98) | NRf | ||
| Nordlinger 2013 | Surgery | 182a | 114 | 64 (25–78) | 102 | 152 (84) | 166 (92) | 67 (37) | 54 (30) | 181 (99) | 76 (42)c |
| FOLFOX/Surgery/FOLFOX | 182b | 127 | 62 (29–79) | 151 (83) | 170 (93) | 61 (34) | 61 (34) | 180 (99) | 78 (43)c | ||
| Ychou 2009 | Surgery/FUFA | 153 | 100 | 64 (34–76) | 42 | NR | 149 (97)d | NR | NR | 148 (97) | 54 (35)e |
| Surgery/FOLFIRI | 153 | 90 | 63 (27–75) | NR | 148 (97)d | NR | NR | 149 (97) | 61 (40)e | ||
| Portier 2006 | Surgery | 85 | 53 | NR | 87 | NR | 81 (95) | NR | NR | NR | NRg |
| Surgery/FUFA | 86 | 46 | NR | NR | 82 (95) | NR | NR | NR | NRg |
a
Nordlinger 2013 – 3 no data.
b
Nordlinger 2013 – 1 no data.
c
Nordlinger 2013 – excluding oxaliplatin chemotherapy.
d
Ychou 2009 – no. of patients with 1–4 liver metastases.
e
Ychou 2009 – excluding irinotecan-based chemotherapy and completed 3 months or more before first trial treatment.
f
Primrose 2014 – previous adjuvant chemotherapy permitted if completed 6 months or more before trial entry, previous rectal chemoradiotherapy permitted if completed 1 month or more before trial entry. No previous systemic chemotherapy for metastatic disease allowed.
g
Portier 2006 – patients receiving chemotherapy in the year preceding liver surgery excluded.